By Marc Dellière, Medical Consultant & Trainer – Specialist in Stress, Prevention & Integrative Health
A patient reports feeling tired after meals and experiencing rapid cravings, despite not eating excessively. For a long time, this type of situation has been interpreted primarily through the lens of behavior.
The emergence of GLP-1 receptor agonists has helped shift that perspective.
These therapies are often described as appetite suppressants. While this is true, it only captures part of their significance.
➡️Their more important contribution may be conceptual: they have brought postprandial physiology back to the center of weight regulation.
GLP-1 is an incretin hormone secreted by intestinal L-cells in response to nutrient intake
Its effects are well established: glucose-dependent stimulation of insulin secretion, suppression of glucagon, delayed gastric emptying, and central modulation of satiety.
Taken together, these mechanisms contribute to a more stable glycemic profile and a better-regulated energy intake.
Human studies confirm that GLP-1 enhances satiety and reduces spontaneous food intake, both in healthy individuals and in patients with type 2 diabetes.
➡️Weight regulation is therefore not only a matter of caloric intake, but also of postprandial signaling quality.
In clinical practice:
A recurring pattern can be observed: a rapid glucose excursion followed by a reactive decline, leading to fatigue, cognitive slowing, and renewed food intake.
This sequence is often interpreted as a behavioral issue, yet it more accurately reflects a dysregulation of metabolic signaling.
➡️ If this is the case, are we sometimes addressing the consequence rather than the cause?
From this perspective, GLP-1–based therapies do not introduce a new mechanism.
They amplify an endogenous regulatory pathway, restoring the organism’s ability to stabilize postprandial responses.
This leads to an important question, particularly in prevention and early metabolic intervention:
➡️ If GLP-1 acts on the signal, could we act earlier, at the level of its generation? One possible approach is to target nutrient kinetics, especially the rate of carbohydrate absorption. By slowing digestion and reducing glucose excursions, it becomes possible to improve metabolic stability and, indirectly, support satiety signaling.
Pep2Dia®, a carb-blocking and GLP-1 boosting ingredient
Within this framework, Pep2Dia®, a milk protein hydrolysate containing the AP dipeptide, operates through partial inhibition of alpha-glucosidase.
This results in delayed carbohydrate digestion and reduced postprandial glycemic peaks, notably without increasing insulin secretion, suggesting an insulin-sparing mechanism.
➡️ In this context, the objective is not to modify hormonal signaling directly, but to act on the conditions under which postprandial signals are generated.
Preclinical results
Recent preclinical studies conducted with Pep2Dia® have also reported changes in circulating GLP-1 levels.
These findings suggest that modulation of carbohydrate digestion and nutrient delivery along the intestine may influence the intestinal environment and, consequently, incretin responses.
➡️ However, this effect appears indirect, likely driven by altered nutrient kinetics and intestinal exposure, and should be interpreted within a broader postprandial regulatory framework rather than as a direct activation of GLP-1 pathways.
In conclusion:
Taken together, these observations support an integrative framework in which two complementary levels of intervention can be distinguished:
- GLP-1 therapies act on hormonal signaling
- Nutritional approaches such as Pep2Dia® act on the conditions under which this signaling is generated
➡️ The common ground between these strategies is postprandial physiology.
Ultimately, this perspective invites a reframing of weight regulation. Rather than focusing exclusively on caloric intake or appetite suppression, it may be more relevant to consider weight as the downstream expression of postprandial metabolic regulation.
➡️ Before attempting to suppress appetite, should we more systematically address the stability of the postprandial response?
Learn more about Pep2Dia for glucose management!
Sources:
Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007.
https://pubmed.ncbi.nlm.nih.gov/17928588/
Flint et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans
https://pmc.ncbi.nlm.nih.gov/articles/PMC508592/
Gutzwiller et al. Glucagon-like peptide-1 reduces food intake in patients with type 2 diabetes mellitus
https://pubmed.ncbi.nlm.nih.gov/10233049/
Gillespie et al. Milk protein hydrolysate reduces postprandial glycemia through alpha-glucosidase inhibition
https://pmc.ncbi.nlm.nih.gov/articles/PMC6683050/
Power et al. Dose-effect of a milk-derived peptide on glucose metabolism in GK rats
https://pmc.ncbi.nlm.nih.gov/articles/PMC8181302/